| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.75▲ | 0.75▲ | 0.76▲ | 0.76▲ | 0.76▲ |
| MA10 | 0.77▲ | 0.77▲ | 0.77▲ | 0.76▲ | 0.75▲ |
| MA20 | 0.78▲ | 0.76▲ | 0.75▲ | 0.75▲ | 0.73▲ |
| MA50 | 0.76▲ | 0.75▲ | 0.75▲ | 0.76▲ | 15.53▼ |
| MA100 | 0.74▲ | 0.73▲ | 0.74▲ | 0.70▲ | 181.34▼ |
| MA200 | 0.75▲ | 0.77▲ | 0.76▲ | 8.29▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.004▼ | -0.001▼ | 0.001▲ | 0.003▲ | 2.328▲ |
| RSI | 54.029▲ | 55.520▲ | 55.793▲ | 53.572▲ | 31.231▼ |
| STOCH | 13.169▼ | 33.994 | 55.137 | 52.515 | 53.709 |
| WILL %R | -32.879 | -25.414 | -25.414 | -27.636 | -52.198 |
| CCI | 30.052 | 45.935 | 66.989 | 59.977 | 1.906 |
|
Tuesday, August 12, 2025 02:05 PM
IRVINE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a biopharmaceutical company seeking an accelerated and full-label U.S. market entry by ...
|
|
Tuesday, March 19, 2024 02:31 PM
– FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – – An interim analysis from the ongoing ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/09/25 | 0.7509 | 0.7796 | 0.7451 | 0.7796 | 99,100 |
| 12/09/25 | 0.80 | 0.80 | 0.76 | 0.78 | 171,800 |
| 11/09/25 | 0.721 | 0.80 | 0.721 | 0.774 | 71,500 |
| 10/09/25 | 0.73 | 0.769 | 0.726 | 0.739 | 54,300 |
| 09/09/25 | 0.732 | 0.749 | 0.73 | 0.749 | 78,000 |
| 08/09/25 | 0.76 | 0.7657 | 0.725 | 0.725 | 73,683 |
| 05/09/25 | 0.77 | 0.79 | 0.732 | 0.763 | 83,600 |
| 04/09/25 | 0.804 | 0.804 | 0.73 | 0.768 | 44,300 |
| 03/09/25 | 0.722 | 0.81 | 0.70 | 0.81 | 134,388 |
| 02/09/25 | 0.7194 | 0.7507 | 0.7194 | 0.743 | 28,222 |
|
|
||||
|
|
||||
|
|